Theriva Biologics, Inc. (TOVX) Financial Ratios
32 years of historical data (1994–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.28
↓-89% vs avg
5yr avg: 2.65
30Y Low0.1·High195.4
ROE
↓
-146.6%
↑-112% vs avg
5yr avg: -69.2%
30Y Low-400%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TOVX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Theriva Biologics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13M | $3M | $2M | $7M | $7M | $829M | $182M | $208M | $87M | $1.6B | $1.8B |
| Enterprise Value | $2M | $-7877454 | $-7684780 | $-14096990 | $-33134167 | $764M | $176M | $194M | $58M | $1.6B | $1.8B |
| P/E Ratio → | -0.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.28 | 0.17 | 0.12 | 0.17 | 0.13 | 12.68 | 34.62 | 18.14 | 3.30 | — | 798.50 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TOVX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TOVX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -146.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -146.6% | -146.6% | -87.3% | -38.9% | -32.8% | -40.4% | -120.0% | -80.7% | -116.0% | — | -316.0% |
| ROA | -68.6% | -68.6% | -56.6% | -28.9% | -27.7% | -36.2% | -78.3% | -64.6% | -54.6% | -73.4% | -102.2% |
| ROIC | -161.2% | -161.2% | -142.7% | -97.0% | -230.1% | — | — | — | — | — | — |
| ROCE | -53.7% | -53.7% | -69.1% | -37.8% | -32.8% | -39.5% | -116.8% | -80.9% | -98.2% | -445.5% | -435.9% |
TOVX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $13M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.08 | 0.05 | 0.03 | 0.02 | 0.09 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.68 | -0.53 | -0.53 | -0.74 | -1.01 | -1.09 | -1.25 | -1.09 | — | -8.47 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($13M) exceeds total debt ($3M)
TOVX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.74x means Theriva Biologics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.07x to 1.74x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Quick Ratio | 1.74 | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Cash Ratio | 1.30 | 1.30 | 1.53 | 3.44 | 5.92 | 18.94 | 2.10 | 2.85 | 8.55 | 1.75 | 0.96 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
TOVX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Theriva Biologics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $1M | $644280 | $613090 | $12M | $2M | $2M | $623244 | $355331 | $269397 |
Peer Comparison
Compare TOVX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TOVXYou | $13M | -0.2 | — | — | — | — | -146.6% | -161.2% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMMP | $64M | -1.4 | — | — | -1117.6% | -2506.5% | -36.9% | -176.9% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 VVOS | $5M | -0.3 | — | — | 60.0% | -74.3% | -266.3% | -422.2% | — |
 SNDX | $2B | -6.2 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TOVX vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonTOVX — Frequently Asked Questions
Quick answers to the most common questions about buying TOVX stock.
What is Theriva Biologics, Inc.'s P/E ratio?
Theriva Biologics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Theriva Biologics, Inc.'s ROE?
Theriva Biologics, Inc.'s return on equity (ROE) is -146.6%. The historical average is -133.0%.
Is TOVX stock overvalued?
Based on historical data, Theriva Biologics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.